Cargando…
A robust prognostic signature for hormone-positive node-negative breast cancer
BACKGROUND: Systemic chemotherapy in the adjuvant setting can cure breast cancer in some patients that would otherwise recur with incurable, metastatic disease. However, since only a fraction of patients would have recurrence after surgery alone, the challenge is to stratify high-risk patients (who...
Autores principales: | Griffith, Obi L, Pepin, François, Enache, Oana M, Heiser, Laura M, Collisson, Eric A, Spellman, Paul T, Gray, Joe W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3961800/ https://www.ncbi.nlm.nih.gov/pubmed/24112773 http://dx.doi.org/10.1186/gm496 |
Ejemplares similares
-
Modeling precision treatment of breast cancer
por: Daemen, Anneleen, et al.
Publicado: (2013) -
Erratum to: Modeling precision treatment of breast cancer
por: Daemen, Anneleen, et al.
Publicado: (2015) -
Prognostic Value of Gene Signatures and Proliferation in Lymph-Node-Negative Breast Cancer
por: Jonsdottir, Kristin, et al.
Publicado: (2014) -
Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature
por: Tutt, Andrew, et al.
Publicado: (2008) -
'Omic approaches to preventing or managing metastatic breast cancer
por: Griffith, Obi L, et al.
Publicado: (2011)